B

Biovaxys Technology Corp
CNSX:BIOV

Watchlist Manager
Biovaxys Technology Corp
CNSX:BIOV
Watchlist
Price: 0.19 CAD -5% Market Closed
Market Cap: 8.1m CAD

Biovaxys Technology Corp
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biovaxys Technology Corp
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
B
Biovaxys Technology Corp
CNSX:BIOV
Operating Expenses
-CA$3.3m
CAGR 3-Years
20%
CAGR 5-Years
-72%
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Operating Expenses
-$343.6m
CAGR 3-Years
-26%
CAGR 5-Years
-85%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Operating Expenses
-$91.1m
CAGR 3-Years
15%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Expenses
-$149.4m
CAGR 3-Years
15%
CAGR 5-Years
-4%
CAGR 10-Years
-20%
Willow Biosciences Inc
TSX:WLLW
Operating Expenses
-CA$9.5m
CAGR 3-Years
26%
CAGR 5-Years
6%
CAGR 10-Years
N/A
NervGen Pharma Corp
XTSX:NGEN
Operating Expenses
-CA$26.5m
CAGR 3-Years
-11%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

Biovaxys Technology Corp
Glance View

Market Cap
8.1m CAD
Industry
N/A

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

BIOV Intrinsic Value
0.003 CAD
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Biovaxys Technology Corp's Operating Expenses?
Operating Expenses
-3.3m CAD

Based on the financial report for Oct 31, 2024, Biovaxys Technology Corp's Operating Expenses amounts to -3.3m CAD.

What is Biovaxys Technology Corp's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-72%

Over the last year, the Operating Expenses growth was 49%. The average annual Operating Expenses growth rates for Biovaxys Technology Corp have been 20% over the past three years , -72% over the past five years .

Back to Top